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Otitis media is one of the most common infectious 
diseases of infancy; a reduction in its incidence would have 
a significant economic and social impact. Vaccines may play 
a role in the prevention of otitis media. This report discusses 
vaccines against pneumococci and influenza viruses. We 
reviewed the literature for results of studies examining the 
role of these vaccines in the prevention of otitis media. The 
23-valent polysaccharide anti-pneumococcal vaccine did not 
modify the incidence of otitis media in children aged 2 years 
less, the age group with the highest incidence of otitis. The 
heptavalent anti-pneumococcal vaccine did not significantly 
reduce the incidence of otitis media overall. This vaccine did, 
however, reduce the number of episodes of otitis media with 
effusion and the number of recurrences; it also altered the 
profile of causative microorganisms by increasing otitis caused 
by different microorganisms. We found the inactivated anti-
influenza virus vaccine to be effective in reducing otitis media 
during peak incidence periods of influenza. As these new 
vaccines are currently available in Brazil, otolaryngologists 
must be aware of their potential role and impact in the 
reduction of otitis media, to counsel patients appropriately.
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INTRODUCTION
Over 75% of children have at least one episode of 
acute otitis media (AOM) by age three years.1 It is estima-
ted that 24.5 million cases of AOM occur annually in the 
USA, which are responsible for 33% of medical visits and 
40% of antibiotic use in children aged below 5 years in 
that country.2 Thus, prevention of otitis media could have 
a significant economic and social impact.
Prevention methods include vaccines, which by 
definition are substances capable of activating an acqui-
red immune response for defending organisms against an 
attack by viruses or bacteria.
In this review we will discuss the antipneumococ-
cal and the inactivated influenza virus vaccines with the 
purpose of introducing these newly available vaccines to 
otorhinolaryngologists and showing their impact on the 
incidence of AOM.
A) 23-valent pneumococcal polysaccharide vaccine:
This vaccine became available in 1983; it is com-
posed of purified polysaccharides from the capsule of 23 
pneumococcal serum types, as follows: 1, 2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 
20, 22F, 23F and 33F, which represent 85% to 90% of the 
serum types that are responsible for invasive disease in 
the USA, and a little over 80% in Brazil.3
Over age 2 years, the efficacy of this vaccine in 
preventing invasive pneumococcal disease is 56 to 81%. 
Efficacy has not been demonstrated - even in immuno-
competent individuals - in the prevention of disease that 
course without bacteremia, such as otitis media.4
Notwithstanding its wide spectrum of action, the 
resulting immune response is T cell independent, that 
is, only B-lymphocytes are stimulated, which generates a 
short-lived response that does not induce immunological 
memory. Thus, an effective immune response is not ge-
nerated in individuals aged below 2 years, particularly if 
otitis media is present.
It is a single-dose vaccine; revaccination is not 
routinely indicated. The indications are:
• Individuals aged over 65 years;
• Individuals aged between 2 and 65 years that are 
at an increased risk of severe pneumococcal infection and 
that are immunocompetent, but with chronic cardiovascu-
lar, pulmonary and hepatic diseases, diabetes, alcoholism, 
cerebrospinal fluid leak, and anatomical or functional 
asplenia (sickle cell disease);
• Individuals aged between 2 and 65 years that are 
at an increased risk of severe pneumococcal infection and 
that are immunodepressed due to human immunodefi-
ciency virus infection, congenital immunodeficiency, leu-
kemia, lymphoma, Hodgkin’s disease, multiple myeloma, 
chronic renal failure or the nephrotic syndrome, following 
bone marrow or solid organ transplantation, or the use of 
immunosuppressant chemotherapy.
B) Heptavalent pneumococcal conjugate vaccine:
The heptavalent vaccine was licensed in February 
2000 in the USA, and is composed of the conjugated form 
of the CRM197 diphtheria protein (Prevnar in the USA, 
Prevenar in Europe) covering the following pneumococcal 
serum types: 4, 6B, 9V, 14, 18C, 19F and 23F.
The vaccination regimen is shown on Table 1, and 
is indicated for:
• All children aged below 2 years
• Children aged between 2 and 5 years and with 
a diagnosis of sickle cell anemia, anatomic or functional 
asplenia, chronic pulmonary or cardiac disease, diabetes, 
chronic renal failure / the nephrotic syndrome, cerebros-
pinal fluid leak and immunosuppressed patients;
• Children that will receive cochlear implants.
Conjugate vaccines consisting of pneumococcal 
capsule polysaccharides conjugated with a carrier protein 
(in this case the CRM197 diphtheria protein) induce T cell-
dependent immunity, resulting in an increased antibody 
response and immunological memory; it is effective from 
birth, which is not the case of the 23-valent polysaccha-
ride vaccine.
Table 1. Recommended heptavalent conjugate pneumococcal 
vaccine regimen in previously non-vaccinated infants and young 
children.
Age at 1st dose 
(months) 
First series    Additional dose
2-6
3 doses at a 2-mon-
th interval    
1 dose at 12-15 
months
7-11
2 doses at a 2-mon-
th interval    
1 dose at 12-15 
months
12-23
2 doses at a 2-mon-
th interval    
Unnecessary
24-59   
Healthy children    1 dose Unnecessary
Children with un-
derlying disease or 
immunosuppression 
2 doses at a 2-mon-
th interval
Unnecessary
The efficacy of the conjugate vaccine against invasi-
ve pneumococcal disease and pneumonia in children has 
been demonstrated in many studies. There has been at 
least an 85% decrease in the incidence of invasive pneu-
mococcal disease caused by the serum types present in 
vaccines, and a 20% decrease in pneumonia, which has 
been demonstrated radiographically.5,6 What decrease 
might be expected in otitis media, considering that:
• Streptococcus pneumonia e causes about 50% 
of AOMs7;
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• Vaccine serum types include about 75% of the 
causing agents of pneumococcal AOM7;
• The estimated efficacy of the heptavalent conju-
gate vaccine is 60%5,8?
There would then be an expected 15 to 20% de-
crease in the general incidence of AOM. Various studies, 
however, have indicated that there has been about a 6% 
decrease.8,9 A substitution phenomenon may explain this 
situation, whereby certain pneumococcal serum types and 
other bacteria not included in the vaccine may have prolife-
rated and occupied the place of those that are included in 
the vaccine. There has been a 27 to 33% increase in pneu-
mococcal AOMs caused by other serum types not included 
in the heptavalent vaccine.6,10,11 Additionally, according to 
Block et al.,12 there has been a proportional increase in 
AOMs caused by H. influenza and M. catarrhalis in post-
vaccination periods (see Table 2) with a corresponding 
decrease in the incidence of pneumococcal AOMs.
tubes. In similar conditions, a Finnish study showed a 
39% decrease.16
The decrease in the incidence of recurring otitis 
media (four episodes within six months or more than five 
episodes within a year) in vaccinated groups was 11.9%;5 
in cases where the infection rate was higher (5 episodes 
within six months or more than six episodes within a year) 
the decrease was 22.8%.5 According to Veenhoven et al.,17 
There was no change in the incidence of recurrences in 
children already with recurring otitis media that received 
the heptavalent vaccine or the 23-valent polysaccharide 
vaccine compared with controls. This suggests that cur-
rently available vaccines appear not to be useful once 
recurrence is installed.
Based on these data, there will be a change in the 
profile of post-heptavalent conjugate vaccine AOM. This 
alteration may be a lower probability that cases caused by 
S. pneumoniae serum types found in vaccines will occur, 
resulting in milder cases and a decreased possibility of 
OME and recurrences. Furthermore, a lower incidence 
of penicillin-resistant S. pneumoniae is also expected, 
followed by an increased incidence of H. influenza and 
M. catarrhalis infections requiring more antibiotics against 
organisms that produce beta-lactamase.
C) The inactivated influenza virus vaccine:
Twenty percent of children with upper airway 
infection by the influenza virus will progress to AOM, 
particularly below age 2 years.18
Inactivated influenza virus vaccination may only 
be used in children aged above 6 months, and should 
be revaccinated annually due to constant virus mutation. 
Children aged below 9 years that are vaccinated for the 
first time should receive a booster vaccine after four to six 
months, followed by annual revaccination.3
In 2003, the North-American Advisory Committee 
on Immunization Practices recommended introducing the 
inactivated influenza virus vaccine in the USA for children 
aged between 6 and 23 months, since this measure - ac-
cording to various studies - reduced hospital admittance.19 
In Brazil, the National Immunization Program recommends 
the influenza virus vaccine as part of the routine vaccina-
tion for individuals aged 60 years or above, and for the 
following risk groups:3
• HIV/AIDS;
• Solid organ and bone marrow transplantation;
• Donors of solid organs and bone marrow regis-
tered in organ donation programs;
• Congenital immunodeficiency, cancer or therapy-
induced immunodeficiency;
• Healthcare professionals and caretakers of immu-
nodepressed patients;
• Chronic cardiac and lung diseases, and asthma;
• Anatomical or functional asplenia;
Table 2. Distribution of bacteria in the etiology of AOM pre-and post-
heptavalent conjugate pneumococcal vaccination.
Block et al.
Pre-vaccination 
period    
Post-vaccination 
period
S. pneumoniae 49% 32%
H. influenza 39% 53%
M. catarrhalis 9% 12%
There are certain significantly prevalent serum types 
in Brazil (1 and 5) not common in the USA, which cause 
up to 20% of pneumococcal infections.13 Vaccine serum 
types compose about 63.5% of the number of pneumo-
coccal infections in Brazil,13 different from the 75% found 
in North-American studies. The expectation for Brazil, 
therefore, is a decrease below 6% in the general incidence 
of AOM.
Pneumococcal antibiotic resistance to penicillin, 
to macrolides and to multiple drugs has been reported 
in five serum types: 6B, 9V, 14, 19F and 23F.14,15 These 
serum types are included in the heptavalent vaccine, and 
a decrease in the number of infections caused by these 
microorganisms is associated with decreased pneumococ-
cal antibiotic resistance.
Since the vaccinated children acted as the main 
bacterial carriers, decreased bacterial dissemination had a 
positive effect also on the non-vaccinated population. The-
re was a decreased circulation of resistant germs, resulting 
in a decreased incidence of pneumococcal infection by 
penicillin-resistant pneumococci in individuals aged be-
tween 20 and 39 years (a 47% decrease) and in individuals 
aged over 65 years (a 37% decrease) when comparing the 
pre- and post-conjugate vaccine period.14
A North-American study5 showed a 20.1% decrease 
in otitis media with effusion (OME) requiring ventilation 
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• Incapacitating chronic neurological diseases;
• Chronic users of acetylsalicylic acid;
• Chronic nephropathy / nephrotic syndrome.
Clement et al.20 and Hekkinen et al.21 demonstrated 
a 32 to 36% decrease in the incidence of AOM during the 
period of maximum prevalence of influenza virus infection 
after using the inactivated influenza virus vaccine.
Hoberman et al.22 showed that there was no change 
in the frequency of AOM in children aged between 6 and 
24 months. This study was hotly contested, for when it 
was undertaken, there was a generally lower incidence of 
influenza; furthermore, the study did not include children 
from nurseries (which are more predisposed to influenza 
infection), and its mean age was lower than comparable 
studies (mean 18 months).
Ozgur et al.23 showed that there was a 50.9% de-
crease in the incidence of AOM in a groups of children 
aged between 6 months and 5 years, compared to controls; 
this study also demonstrated a 26.7% decrease in the total 
number of cases of otitis media with effusion in a 6-month 
follow-up period.
FINAL COMMENTS
The heptavalent pneumococcal vaccine, although 
not decreasing significantly the general incidence of AOM, 
alters the microbiological profile of this disease; there is 
a lower incidence of antibiotic-resistant pneumococcal 
serum types, a lower incidence of recurring otitis media 
and of otitis media with effusion. Additionally, a possible 
reduction in antibiotic use may be expected, as less viru-
lent microorganisms will become a more frequent cause 
of AOM.
The currently available inactivated influenza virus 
vaccine in Brazil leads to a decreased incidence of sea-
sonal AOM, during the period in which virus infection is 
higher. There was, however, no change in the final result 
during other periods and in children with no risk factors 
or influenza, compared to controls.
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